On December 23, it was announced that IDIBELL was the recipient of five grants in the call for the state program for scientific and technical research. The purpose of these grants is to promote collaborative projects between public and private institutions for the transfer of knowledge and innovation in health, and are part of the state plan for scientific, technical and innovation research 2021-2023, within the framework of the recovery plan, transformation and resilience, from the Ministry of Economic Affairs and Digital Transformation (MINECO).
Among the projects financed, the one for precision radiotherapy for breast cancer stands out, or both clinical trials to evaluate the effects of the administration of ApTOLL in patients with stroke and myocardial infarction. On the other hand, other projects financed seek new approaches for the diagnosis of endometrial cancer and the search for therapies for Ewing’s sarcoma.
In total, the five projects will receive funding of more than 1.2 million for scientific research and innovation in health. IDIBELL celebrates this news as a fundamental impulse for its commitment to the health and well-being of society.
Title: radioterapia de precisión: firma molecular predictiva para radiosensibilidad en cáncer de mama
Principal Investigator: Ferran Guedea
Funded: 110.013,00 €
Title: Clinical trial to evaluate the administration of ApTOLL in ambulances and the neuroprotective effect in stroke patients. RACETOLL
Principal Investigator: Pere Cardona Portela
Funded: 487.992,80 €
Title: Clinical trial to evaluate the administration of ApTOLL in Acute Myocardial Infarction. APSTEMI
Principal Investigator: Joan Antoni Gomez Hospital
Funded: 259.100,89 €
Title: Womec advanced: nuevas aproximaciones para el diagnóstico de cáncer de endometrio
Principal Investigator: Laura Costas Caudet
Funded: 194.288,00 €
Title: traslación a la clínica de una nueva terapia dirigida para el tratamiento del sarcoma de ewing
Principal Investigator: Oscar Martínez Tirado
Funded: 199.904,74 €
Funded by MCIN/AEI/10.13039/501100011033 and by the European Union-NextGenerationEU/PRT